Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Relapsed/Refractory NPM1-m Acute Leukemia

Tundra lists 1 Relapsed/Refractory NPM1-m Acute Leukemia clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06376162

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).

Gender: All

Ages: 0 Years - 21 Years

Updated: 2025-10-20

16 states

Relapsed/Refractory KMT2A-r Acute Leukemia

Relapsed/Refractory NUP98-r Acute Leukemia

Relapsed/Refractory NPM1-m Acute Leukemia